Nuzenio

Immuneering Corporation

Immuneering Corporation news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 13 latest news signals 8 publisher sources 100/100 entity strength

Latest news

IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - StocktwitsStocktwits · Fri, 07 Aug 2026 18:34:48 GMTIMMUNEERING CORPORATION : H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING - BitgetBitget · Thu, 06 Aug 2026 23:25:51 GMTImmuneering Corporation Stock 12‑Month Price Target Cut to $17.57, Implies 300% Upside - TradingViewTradingView · Thu, 06 Aug 2026 17:20:18 GMTH.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy - StreetInsiderStreetInsider · Thu, 06 Aug 2026 10:12:22 GMTImmuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 12:01:01 GMTIMRX: Advanced pivotal trial for atebimetinib, strong cash runway, and widened net loss on higher R&D - TradingViewTradingView · Wed, 05 Aug 2026 11:43:32 GMTImmuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingViewTradingView · Wed, 05 Aug 2026 11:43:03 GMTImmuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - Quiver QuantitativeQuiver Quantitative · Wed, 05 Aug 2026 11:43:00 GMT

Timeline

Fri, 07 Aug 2026 18:34:48 GMTIMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Thu, 06 Aug 2026 23:25:51 GMTIMMUNEERING CORPORATION : H.C. WAINWRIGHT INITIATES COVERAGE WITH BUY RATING - Bitget
Thu, 06 Aug 2026 17:20:18 GMTImmuneering Corporation Stock 12‑Month Price Target Cut to $17.57, Implies 300% Upside - TradingView
Thu, 06 Aug 2026 10:12:22 GMTH.C. Wainwright Starts Immuneering Corporation (IMRX) at Buy - StreetInsider
Wed, 05 Aug 2026 12:01:01 GMTImmuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Wed, 05 Aug 2026 11:43:32 GMTIMRX: Advanced pivotal trial for atebimetinib, strong cash runway, and widened net loss on higher R&D - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Immuneering Corporation.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.